BLUE BELL, PA --- Wingspan Technology announced the release of SiteZone, a solution for collaboration between sponsors, CROs, and site personnel. The cloud-based product provides one location for collecting and tracking investigator content.
Designed for the average internet user, SiteZone features an intuitive user interface, requiring little or no training at the site level. Investigators can access and sign certain eTMF documents, as well as upload documents that originate on site. Administrators can track the progress of individual sites and easily view missing documents.
“Clinical trials often require a global reach. SiteZone improves the overall workflow and saves time and resources throughout the course of a trial,” Wingspan CEO Troy Deck said. “We are offering Sponsors and CROs a way to quicken study startup, reduce costs for paper and site visits, and improve overall efficiency.”
SiteZone is comparable to site portal solutions. It features the components needed to manage user access, support site users, and expedite the collection and delivery of documents. Personal credentials are created and managed by Wingspan, taking the burden away from sponsors, and allowing site personnel to use SiteZone across trials and sponsors. SiteZone’s electronic signature feature makes it easy for sites to sign and submit documents and also eliminates the need for on-site storage of many paper documents.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.